Value | Commercial | Access

France PLFSS 2023: Social security financing bill puts pressure on medicine pricing

The draft of the French social security financing law for the year to come (PLFSS 2023) includes a few proposals that could have an impact on innovative medicine pricing, including ATMPs and products eligible for the “European price”, meaning products that have demonstrated improvement over existing therapies.

It looks like a theme of more benchmarking to existing therapies’ prices, and pricing in line with the label’s indication(s).

For medical devices, the proposed changes could present a real opportunity to optimse and tailor the pricing approach, as well as optimise early access schemes; but as always… the devil’s in the operationalisation…

Other recent posts: